Inhibitory effect of six herbal extracts on CYP2C8 enzyme activity in human liver microsomes

References

• Baldwin SJ, Clarke SE, Chenery RJ. (1999). Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone. Br J Clin Pharmacol 48:424–32
   PubMed Web of Science ®Google Scholar
• Bidstrup TB, Bjørnsdottir I, Sidelmann UG, et al. (2003). CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide. Br J Clin Pharmacol 56:305–14
   PubMed Web of Science ®Google Scholar
• Bun SS, Ciccolini J, Bun H, et al. (2003). Drug interactions of paclitaxel metabolism in human liver microsomes. J Chemother 15:266–74
   PubMed Web of Science ®Google Scholar
• de Lima Toccafondo Vieira M, Huang SM. (2012). Botanical–drug interactions: a scientific perspective. Planta Med 78:1400–15
   Google Scholar
• Deng LJ, Wang F, Li HD. (2005). Effect of gemfibrozil on the pharmacokinetics of pioglitazone. Eur J Clin Pharmacol 61:831–6
   PubMed Web of Science ®Google Scholar
• Dravid PV, Frye RF. (2008). Determination of N-desethylamodiaquine by hydrophilic interaction liquid chromatography with tandem mass spectrometry: application to in vitro drug metabolism studies. J Chromatogr B Analyt Technol Biomed Life Sci 863:129–34
   PubMed Web of Science ®Google Scholar
• Duthie SJ, Jenkinson AM, Crozier A, et al. (2006). The effects of cranberry juice consumption on antioxidant status and biomarkers relating to heart disease and cancer in healthy human volunteers. Eur J Nutr 45:113–22
   PubMed Web of Science ®Google Scholar
• Etheridge AS, Black SR, Patel PR, et al. (2007). An in vitro evaluation of cytochrome P450 inhibition and P-glycoprotein interaction with goldenseal, Ginkgo biloba, grape seed, milk thistle, and ginseng extracts and their constituents. Planta Med 73:731–41
   PubMed Web of Science ®Google Scholar
• Evans WE, Relling MV. (2004). Moving towards individualized medicine with pharmacogenomics. Nature 429:464–8
   PubMed Web of Science ®Google Scholar
• FDA. (2012). Draft guidance for industry: drug interaction studies – study design, data analysis, implications for dosing, and labeling recommendations. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm292362.pdf [last accessed 27 Oct 2014]
   Google Scholar
• FDA. (2013). Draft guidance for industry: bioanalytical method validation. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM368107.pdf [last accessed 27 Oct 2014]
   Google Scholar
• Foti RS, Pearson JT, Rock DA, et al. (2009). In vitro inhibition of multiple cytochrome P450 isoforms by xanthone derivatives from mangosteen extract. Drug Metab Dispos 37:1848–55
   PubMed Web of Science ®Google Scholar
• Frank A, Unger M. (2006). Analysis of frankincense from various Boswellia species with inhibitory activity on human drug metabolising cytochrome P450 enzymes using liquid chromatography mass spectrometry after automated on-line extraction. J Chromatogr A 1112:255–62
   PubMed Web of Science ®Google Scholar
• Gardiner P, Phillips R, Shaughnessy AF. (2008). Herbal and dietary supplement–drug interactions in patients with chronic illnesses. Am Fam Physician 77:73–8
   PubMed Web of Science ®Google Scholar
• Gray IC, Nobile C, Muresu R, et al. (1995). A 2.4-megabase physical map spanning the CYP2C gene cluster on chromosome 10q24. Genomics 28:328–32
   PubMed Web of Science ®Google Scholar
• Guay DR. (2009). Cranberry and urinary tract infections. Drugs 69:775–807
   PubMed Web of Science ®Google Scholar
• Gurley BJ, Fifer EK, Gardner Z. (2012). Pharmacokinetic herb–drug interactions (part 2): drug interactions involving popular botanical dietary supplements and their clinical relevance. Planta Med 78:1490–514
   PubMed Web of Science ®Google Scholar
• He M, Jiang J, Qiu F, et al. (2013). Inhibitory effects of gypenosides on seven human cytochrome P450 enzymes in vitro. Food Chem Toxicol 57:262–5
   Google Scholar
• Hellum BH, Hu Z, Nilsen OG. (2007). The induction of CYP1A2, CYP2D6 and CYP3A4 by six trade herbal products in cultured primary human hepatocytes. Basic Clin Pharmacol Toxicol 100:23–30
   PubMed Web of Science ®Google Scholar
• Hermann R, von Richter O. (2012). Clinical evidence of herbal drugs as perpetrators of pharmacokinetic drug interactions. Planta Med 78:1458–77
   PubMed Web of Science ®Google Scholar
• Holt RR, Lazarus SA, Sullards MC, et al. (2002). Procyanidin dimer B2 [epicatechin-(4beta-8)-epicatechin] in human plasma after the consumption of a flavanol-rich cocoa. Am J Clin Nutr 76:798–804
   PubMed Web of Science ®Google Scholar
• Hruska MW, Amico JA, Langaee TY, et al. (2005). The effect of trimethoprim on CYP2C8 mediated rosiglitazone metabolism in human liver microsomes and healthy subjects. Br J Clin Pharmacol 59:70–9
   PubMedGoogle Scholar
• Jaakkola T, Backman JT, Neuvonen M, Neuvonen PJ. (2005). Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. Clin Pharmacol Ther 77:404–14
   PubMed Web of Science ®Google Scholar
• Jaakkola T, Laitila J, Neuvonen PJ, Backman JT. (2006). Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors. Basic Clin Pharmacol Toxicol 99:44–51
   PubMed Web of Science ®Google Scholar
• Jenkins SM, Zvyaga T, Johnson SR, et al. (2011). Studies to further investigate the inhibition of human liver microsomal CYP2C8 by the acyl-β-glucuronide of gemfibrozil. Drug Metab Dispos 39:2421–30
   PubMed Web of Science ®Google Scholar
• Kim KA, Park PW, Kim HK, et al. (2005). Effect of quercetin on the pharmacokinetics of rosiglitazone, a CYP2C8 substrate, in healthy subjects. J Clin Pharmacol 45:941–6
   PubMed Web of Science ®Google Scholar
• Lai XS, Yang LP, Li XT, et al. (2009). Human CYP2C8: structure, substrate specificity, inhibitor selectivity, inducers and polymorphisms. Curr Drug Metab 10:1009–47
   PubMed Web of Science ®Google Scholar
• Lamb DC, Waterman MR, Kelly SL, Guengerich FP. (2007). Cytochromes P450 and drug discovery. Curr Opin Biotechnol 18:504–12
   PubMed Web of Science ®Google Scholar
• Li XQ, Björkman A, Andersson TB, et al. (2002). Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate. J Pharmacol Exp Ther 300:399–407
   PubMed Web of Science ®Google Scholar
• Lindstrom AOC, Lynch ME, Blumenthal M. (2013). Herb supplement sales increase 5.5% in 2012: herbal supplement sales rise for 9th consecutive year; turmeric sales jump 40% in natural channel. HerbalGram 99:60–5
   Google Scholar
• Marill J, Cresteil T, Lanotte M, Chabot GG. (2000). Identification of human cytochrome P450s involved in the formation of all-trans-retinoic acid principal metabolites. Mol Pharmacol 58:1341–8
   PubMed Web of Science ®Google Scholar
• Milbury PE, Vita JA, Blumberg JB. (2010). Anthocyanins are bioavailable in humans following an acute dose of cranberry juice. J Nutr 140:1099–104
   PubMed Web of Science ®Google Scholar
• Misaka S, Kawabe K, Onoue S, et al. (2013). Effects of green tea catechins on cytochrome P450 2B6, 2C8, 2C19, 2D6 and 3A activities in human liver and intestinal microsomes. Drug Metab Pharmacokinet 28:244–9
   PubMed Web of Science ®Google Scholar
• Muthiah YD, Ong CE, Sulaiman SA, et al. (2012). In-vitro inhibitory effect of Tualang honey on cytochrome P450 2C8 activity. J Pharm Pharmacol 64:1761–9
   Google Scholar
• Naraharisetti SB, Lin YS, Rieder MJ, et al. (2010). Human liver expression of CYP2C8: gender, age, and genotype effects. Drug Metab Dispos 38:889–93
   Google Scholar
• Natural Medicines Comrehensive Databases. AccessPharmacy. Available at: http://accesspharmacy.mhmedical.com/HerbsandSupplements.aspx [last accessed 27 Aug 2014]
   Google Scholar
• Neto CC. (2007). Cranberry and its phytochemicals: a review of in vitro anticancer studies. J Nutr 137:186S–93S
   PubMed Web of Science ®Google Scholar
• Niemi M, Backman JT, Granfors M, et al. (2003a). Gemfibrozil considerably increases the plasma concentrations of rosiglitazone. Diabetologia 46:1319–23
   PubMed Web of Science ®Google Scholar
• Niemi M, Backman JT, Neuvonen M, Neuvonen PJ. (2003b). Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. Diabetologia 46:347–51
   PubMed Web of Science ®Google Scholar
• Niemi M, Backman JT, Neuvonen PJ. (2004a). Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone. Clin Pharmacol Ther 76:239–49
   PubMed Web of Science ®Google Scholar
• Niemi M, Kajosaari LI, Neuvonen M, et al. (2004b). The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects. Br J Clin Pharmacol 57:441–7
   PubMed Web of Science ®Google Scholar
• Ogilvie BW, Zhang D, Li W, et al. (2006). Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions. Drug Metab Dispos 34:191–7
   PubMed Web of Science ®Google Scholar
• Pan Y, Tiong KH, Abd-Rashid BA, et al. (2012). Inhibitory effects of cytochrome P450 enzymes CYP2C8, CYP2C9, CYP2C19 and CYP3A4 by Labisia pumila extracts. J Ethnopharmacol 143:586–91
   Google Scholar
• Pang CY, Mak JW, Ismail R, Ong CE. (2012). In vitro modulatory effects of flavonoids on human cytochrome P450 2C8 (CYP2C8). Naunyn Schmiedebergs Arch Pharmacol 385:495–502
   PubMed Web of Science ®Google Scholar
• Parikh S, Ouedraogo JB, Goldstein JA, et al. (2007). Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: implications for malaria treatment in Africa. Clin Pharmacol Ther 82:197–203
   PubMed Web of Science ®Google Scholar
• Peregoy JA, Clarke TC, Jones LI, et al. (2014). Regional variation in use of complementary health approaches by US adults. NCHS Data Brief 146:1–8
   PubMedGoogle Scholar
• Posadzki P, Watson L, Ernst E. (2013). Herb–drug interactions: an overview of systematic reviews. Br J Clin Pharmacol 75:603–18
   PubMed Web of Science ®Google Scholar
• Qi XY, Liang SC, Ge GB, et al. (2013). Inhibitory effects of sanguinarine on human liver cytochrome P450 enzymes. Food Chem Toxicol 56:392–7
   PubMed Web of Science ®Google Scholar
• Sano A, Yamakoshi J, Tokutake S, et al. (2003). Procyanidin B1 is detected in human serum after intake of proanthocyanidin-rich grape seed extract. Biosci Biotechnol Biochem 67:1140–3
   PubMed Web of Science ®Google Scholar
• Schoch GA, Yano JK, Wester MR, et al. (2004). Structure of human microsomal cytochrome P450 2C8. Evidence for a peripheral fatty acid binding site. J Biol Chem 279:9497–503
   PubMed Web of Science ®Google Scholar
• Sevior DK, Hokkanen J, Tolonen A, et al. (2010). Rapid screening of commercially available herbal products for the inhibition of major human hepatic cytochrome P450 enzymes using the N-in-one cocktail. Xenobiotica 40:245–54
   PubMed Web of Science ®Google Scholar
• Shi S, Klotz U. (2012). Drug interactions with herbal medicines. Clin Pharmacokinet 51:77–104
   PubMed Web of Science ®Google Scholar
• Strandell J, Neil A, Carlin G. (2004). An approach to the in vitro evaluation of potential for cytochrome P450 enzyme inhibition from herbals and other natural remedies. Phytomedicine 11:98–104
   PubMed Web of Science ®Google Scholar
• Tornio A, Niemi M, Neuvonen M, et al. (2008a). The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo. Clin Pharmacol Ther 84:403–11
   PubMed Web of Science ®Google Scholar
• Tornio A, Niemi M, Neuvonen PJ, Backman JT. (2008b). Trimethoprim and the CYP2C8*3 allele have opposite effects on the pharmacokinetics of pioglitazone. Drug Metab Dispos 36:73–80
   PubMed Web of Science ®Google Scholar
• Totah RA, Rettie AE. (2005). Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance. Clin Pharmacol Ther 77:341–52
   PubMed Web of Science ®Google Scholar
• Tracy TS, Kingston RL. (2007). Herbal products: toxicology and clinical pharmacology. Totowa (NJ): Humana Press
   Google Scholar
• Unger M, Frank A. (2004). Simultaneous determination of the inhibitory potency of herbal extracts on the activity of six major cytochrome P450 enzymes using liquid chromatography/mass spectrometry and automated online extraction. Rapid Commun Mass Spectrom 18:2273–81
   PubMed Web of Science ®Google Scholar
• VandenBrink BM, Foti RS, Rock DA, et al. (2011). Evaluation of CYP2C8 inhibition in vitro: utility of montelukast as a selective CYP2C8 probe substrate. Drug Metab Dispos 39:1546–54
   PubMed Web of Science ®Google Scholar
• Vuppugalla R, Chang SY, Zhang H, et al. (2007). Effect of commonly used organic solvents on the kinetics of cytochrome P450 2B6- and 2C8-dependent activity in human liver microsomes. Drug Metab Dispos 35:1990–5
   PubMed Web of Science ®Google Scholar
• Walsky RL, Gaman EA, Obach RS. (2005). Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol 45:68–78
   PubMed Web of Science ®Google Scholar
• Wang JS, Neuvonen M, Wen X, et al. (2002). Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes. Drug Metab Dispos 30:1352–6
   PubMed Web of Science ®Google Scholar
• Whitten DL, Myers SP, Hawrelak JA, Wohlmuth H. (2006). The effect of St John's wort extracts on CYP3A: a systematic review of prospective clinical trials. Br J Clin Pharmacol 62:512–26
   PubMed Web of Science ®Google Scholar
• Zanger UM, Schwab M. (2013). Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 138:103–41
   PubMed Web of Science ®Google Scholar
• Zheng W, Wang SY. (2003). Oxygen radical absorbing capacity of phenolics in blueberries, cranberries, chokeberries, and lingonberries. J Agric Food Chem 51:502–9
   PubMed Web of Science ®Google Scholar